Boothbay Fund Management LLC Buys 118,994 Shares of Pharvaris N.V. $PHVS

Boothbay Fund Management LLC grew its position in shares of Pharvaris N.V. (NASDAQ:PHVS) by 735.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 135,181 shares of the company’s stock after acquiring an additional 118,994 shares during the quarter. Boothbay Fund Management LLC owned 0.26% of Pharvaris worth $3,373,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in PHVS. TFG Asset Management GP Ltd increased its position in shares of Pharvaris by 48.1% during the second quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company’s stock valued at $3,311,000 after acquiring an additional 61,105 shares during the last quarter. General Atlantic L.P. lifted its holdings in Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after acquiring an additional 500,000 shares during the period. Patient Square Capital LP boosted its position in Pharvaris by 41.4% in the third quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock worth $8,617,000 after purchasing an additional 101,098 shares during the last quarter. Integral Health Asset Management LLC purchased a new position in Pharvaris in the third quarter worth $4,990,000. Finally, Palumbo Wealth Management LLC grew its stake in Pharvaris by 14.4% in the 3rd quarter. Palumbo Wealth Management LLC now owns 16,641 shares of the company’s stock valued at $415,000 after purchasing an additional 2,092 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Oppenheimer lifted their target price on Pharvaris from $44.00 to $50.00 and gave the stock an “outperform” rating in a research note on Thursday, December 4th. Morgan Stanley increased their price target on shares of Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a research report on Thursday, December 4th. Guggenheim raised their price objective on shares of Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Thursday, January 22nd. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $41.70.

Pharvaris Stock Performance

Shares of Pharvaris stock opened at $26.93 on Tuesday. Pharvaris N.V. has a 52-week low of $11.51 and a 52-week high of $29.80. The stock’s 50-day simple moving average is $26.73 and its 200 day simple moving average is $25.02.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.